Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(Q1)Jul 31, 2024 | (FY)Apr 30, 2024 | (Q4)Apr 30, 2024 | (Q3)Jan 31, 2024 | (Q2)Oct 31, 2023 | (Q1)Jul 31, 2023 | (FY)Apr 30, 2023 | (Q4)Apr 30, 2023 | (Q3)Jan 31, 2023 | (Q2)Oct 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -16.90%7.44B | 26.26%32B | 46.98%8.72B | 4.72%7.79B | 8.25%6.54B | 50.87%8.95B | 78.91%25.34B | 48.19%5.93B | 7.43B | 6.04B |
Cost of revenue | -8.11%3.94B | 22.00%16.79B | 34.53%4.5B | 22.37%4.53B | 3.07%3.48B | 28.16%4.28B | 68.24%13.76B | 40.14%3.34B | 3.7B | 3.37B |
Gross profit | -24.97%3.5B | 31.32%15.21B | 63.04%4.23B | -12.80%3.25B | 14.78%3.07B | 80.20%4.66B | 93.51%11.58B | 60.03%2.59B | 3.73B | 2.67B |
Operating expense | 25.89%780.54M | 31.09%2.84B | 30.92%904.65M | 30.58%693.95M | 29.78%626.16M | 33.27%620M | 21.02%2.17B | 22.44%691M | 531.44M | 482.48M |
Operating profit | -32.77%2.72B | 31.37%12.36B | 74.72%3.32B | -20.01%2.56B | 11.47%2.44B | 90.48%4.04B | 124.53%9.41B | 80.13%1.9B | 3.2B | 2.19B |
Net non-operating interest income (expenses) | 52.54%-243K | 57.44%-1.46M | 49.71%-261K | 67.83%-340K | 59.86%-348K | 48.28%-512K | 34.66%-3.43M | 48.10%-519K | -1.06M | -867K |
Non-operating interest income | --31K | 88.57%132K | 82.93%75K | --0 | 96.55%57K | --0 | 79.49%70K | 86.36%41K | --0 | --29K |
Non-operating interest expense | -46.48%274K | -54.52%1.59M | -40.00%336K | -67.83%340K | -54.80%405K | -48.28%512K | -33.82%3.5M | -45.21%560K | --1.06M | --896K |
Net investment income | 99.65%-44K | -190.37%-5M | 126.04%667K | 112.78%1M | -46.33%5.84M | -469.64%-12.52M | 74.58%-1.72M | 68.84%-2.56M | -7.85M | 10.89M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | -12M | |||||||||
Less:Other special charges | --12M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Other non-operating income (expenses) | 114.21%564K | -131.61%-13.79M | -85.82%37K | -119.51%-9.89M | -6.25%30K | 45.94%-3.97M | 245.28%43.63M | 100.91%261K | 50.68M | 32K |
Income before tax | -32.78%2.71B | 30.62%12.34B | 75.00%3.32B | -21.33%2.55B | 11.22%2.44B | 90.62%4.03B | 136.29%9.45B | 84.59%1.9B | 3.24B | 2.2B |
Income tax | -32.70%827.49M | 31.49%3.62B | 99.25%864.9M | -21.62%778.68M | 10.10%742.53M | 89.80%1.23B | 128.08%2.75B | 47.23%434.09M | 993.51M | 674.4M |
Net income | -32.81%1.88B | 30.26%8.73B | 67.82%2.46B | -21.20%1.77B | 11.71%1.7B | 90.99%2.8B | 139.83%6.7B | 99.61%1.46B | 2.25B | 1.52B |
Net income continuous operations | -32.81%1.88B | 30.26%8.73B | 67.82%2.46B | -21.20%1.77B | 11.71%1.7B | 90.99%2.8B | 139.83%6.7B | 99.61%1.46B | --2.25B | --1.52B |
Noncontrolling interests | ||||||||||
Net income attributable to the company | -32.81%1.88B | 30.26%8.73B | 67.82%2.46B | -21.20%1.77B | 11.71%1.7B | 90.99%2.8B | 139.83%6.7B | 99.61%1.46B | 2.25B | 1.52B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -32.81%1.88B | 30.26%8.73B | 67.82%2.46B | -21.20%1.77B | 11.71%1.7B | 90.99%2.8B | 139.83%6.7B | 99.61%1.46B | 2.25B | 1.52B |
Gross dividend payment | ||||||||||
Basic earnings per share | -4.28%43.13 | 26.04%139.63 | 66.06%39.34 | -24.40%28.17 | 6.54%27.06 | 84.45%45.06 | 137.53%110.78 | 93.48%23.69 | 37.26 | 25.4 |
Diluted earnings per share | 0.00%43.13 | 29.89%135.18 | 69.49%38.22 | -20.86%27.51 | 12.72%26.32 | 84.24%43.13 | 123.14%104.07 | 84.22%22.55 | 34.76 | 23.35 |
Dividend per share | ||||||||||
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |